Doctor of Osteopathy Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Douglas Denham

Family Medicine San Antonio, TX Doctor of Osteopathy

NPI 1467533893 CMS profile 338445

7400 Crestway, San Antonio, TX 78233

Open in the dashboard

General payments

$2,562

20 records reported · program years 2019–2024

Research payments

$87,699

Paid to them · 19 records reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$68,544,225 paid to institutions, not to them · program years 2019–2025

Through program year 2024, Douglas Denham of San Antonio, TX is reported in the CMS Open Payments database as having received $2,562 across 20 general payments and $87,699 in research payments paid to them. Separately, studies naming them as principal investigator received $68,544,225 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

11 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $319 3
2024 Research $61,137 2
2023 General $148 2
2023 Research $1,883 4
2022 General $82 3
2022 Research $7,239 6
2021 General $83 3
2020 General $15 1
2020 Research $11,086 4
2019 General $1,915 8
2019 Research $6,353 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Douglas Denham
  • Family Medicine median
  • Middle half of Family Medicine
  • National median

In program year 2025, general payments to Douglas Denham were reported at $0. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.

Show as a table
Year Douglas Denham Family Medicine median Middle half National median
2019 $1,915 $150 $41–$543 $163
2020 $15 $120 $32–$415 $114
2021 $83 $137 $35–$551 $132
2022 $82 $137 $37–$512 $149
2023 $148 $149 $42–$545 $160
2024 $319 $156 $44–$560 $164
2025 $0 $155 $45–$549 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Pfizer Inc. $1,834 7 payments
  2. Zealand Pharma A/S $294 2 payments
  3. Novo Nordisk Inc $197 4 payments
  4. Rhythm Pharmaceuticals, Inc. $99 3 payments
  5. Regeneron Pharmaceuticals, Inc. $60 1 payment
  6. Intercept Pharmaceuticals, Inc. $41 1 payment
  7. Merck Sharp & Dohme Corporation $22 1 payment
  8. Dexcom, Inc. $15 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $1,512 14 payments
  2. Travel and Lodging $997 4 payments
  3. Education $32 1 payment
  4. Gift $20 1 payment
Products named General payments · program years 2019–2024
  1. PREVNAR - 13 $1,202 4 payments
  2. PRALUENT $60 1 payment
  3. Ozempic $44 2 payments
  4. OCALIVA $41 1 payment
  5. Imcivree $35 1 payment
  6. Dexcom G6 CGM System $15 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2024
  1. Eli Lilly and Company $81,100 14 payments
  2. Pfizer Inc. $6,400 2 payments
  3. Novo Nordisk AS $121 2 payments
  4. Gilead Sciences, Inc. $78 1 payment

Records

39 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Family Medicine in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record